Patent ID: 8753682

Claim:
A dual release oral tablet of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof, said tablet comprising: a) 20% by weight of the dexlansoprazole in powder form; b) 80% by weight of the dexlansoprazole in granule form, said granule further comprising talc, colloidal silicon dioxide, magnesium stearate, hydrophobic agents, an alkali compound, fillers, binders, disintegrants or their mixtures, wherein the granule form is of different particle size than the powder form; and c) a single enteric coating that dissolves at between pH 5.5 and 6.4, wherein, upon oral administration, the tablet achieves dual release of the dexlansoprazole in the small intestine at pH 5.5 and then at pH 6.5, with prevention of dose dumping of the dexlansoprazole.